Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
BOSTON, May 15, 2013 /PRNewswire/ -- Solos Endoscopy, Inc. (OTCPK: SNDY), a provider of quality innovative healthcare instruments to Hospitals across the Country, reported sales and earnings results for the full year ended December 31, 2012.
In addition, the Company’s President, Robert Segersten, posted a Letter to Shareholders outlining recent announcements and updates on the Company’s progress as it relates to its product lines and pursuit of ISO 13485 certification and CE Mark for its MammoView® devices.
The Company’s financial results, disclosure statement and President’s Letter can be found on the OTC Markets website (http://www.otcmarkets.com/stock/SNDY/financials).
About Solos Endoscopy, Inc.:
Solos Endoscopy is celebrating its 25th Year of providing quality innovative healthcare instruments to Hospitals across the Country. For more than 25 Years, from medical schools to hospitals, surgeons have trusted Solos Endoscopy to develop and market breakthrough technology, applications, medical devices, and procedural techniques for the screening, diagnosis, treatment and management of disease and medical conditions.
For more information on TUV SUD America visit www.tuvamerica.com.
Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications that may arise could prevent the prompt implementation of any strategically significant plan(s) outlined above. The company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the company’s Annual Report filing and other filings with the OTC Markets Group (available at www.otcmarkets.com). The company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events, or otherwise.
Source: Solos Endoscopy, Inc.
Investor Relations
(617) 360-9719
SOURCE Solos Endoscopy, Inc.
Help employers find you! Check out all the jobs and post your resume.
